---
schema_version: "secwatch.filing_event.v1"
accession: "0001816590-25-000149"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:41:25.432526+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Compass Pathways accelerates COMP360 TRD launch by 9-12 months; Q3 net loss $137.7M

## Summary
- Accelerating commercialization readiness by 9-12 months after positive FDA meeting on NDA strategy including potential rolling submission.
- COMP006 9-week data and COMP005 26-week data expected Q1 2026; COMP006 26-week data expected early Q3 2026.
- Cash $185.9M as of Sept 30, 2025; full-year 2025 net cash used in operations expected $120M-$145M.
- Q3 2025 net loss $137.7M ($1.44/share) includes $101.3M non-cash loss on warrant fair value adjustment.
- R&D expenses $27.3M in Q3 2025 vs $32.9M in Q3 2024, down due to discontinued discovery programs.

## SEC filing metadata
- accession: 0001816590-25-000149
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000181659025000149/0001816590-25-000149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000181659025000149/cmps-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001816590-25-000149
- JSON: https://secwatch.observer/filing/0001816590-25-000149.json
- Plain text: https://secwatch.observer/filing/0001816590-25-000149.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.